ID   SYGP1_HUMAN             Reviewed;        1343 AA.
AC   Q96PV0; A2AB17; A2BEL6; A2BEL7; A8MQC4; Q8TCS2; Q9UGE2;
DT   15-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   26-JUN-2007, sequence version 4.
DT   18-JUN-2025, entry version 194.
DE   RecName: Full=Ras/Rap GTPase-activating protein SynGAP;
DE   AltName: Full=Neuronal RasGAP;
DE   AltName: Full=Synaptic Ras GTPase-activating protein 1;
DE            Short=Synaptic Ras-GAP 1;
GN   Name=SYNGAP1; Synonyms=KIAA1938;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11572484; DOI=10.1093/dnares/8.4.179;
RA   Nagase T., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XXI. The
RT   complete sequences of 60 new cDNA clones from brain which code for large
RT   proteins.";
RL   DNA Res. 8:179-187(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 384-1343 (ISOFORM 2).
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   INTERACTION WITH MPDZ.
RX   PubMed=15312654; DOI=10.1016/j.neuron.2004.08.003;
RA   Krapivinsky G., Medina I., Krapivinsky L., Gapon S., Clapham D.E.;
RT   "SynGAP-MUPP1-CaMKII synaptic complexes regulate p38 MAP kinase activity
RT   and NMDA receptor-dependent synaptic AMPA receptor potentiation.";
RL   Neuron 43:563-574(2004).
RN   [5]
RP   INVOLVEMENT IN MRD5, AND VARIANTS GLU-201; GLN-749; ASN-790; THR-1115;
RP   LEU-1283 AND MET-1310.
RX   PubMed=19196676; DOI=10.1056/nejmoa0805392;
RG   Synapse to disease group;
RA   Hamdan F.F., Gauthier J., Spiegelman D., Noreau A., Yang Y., Pellerin S.,
RA   Dobrzeniecka S., Cote M., Perreault-Linck E., Carmant L., D'Anjou G.,
RA   Fombonne E., Addington A.M., Rapoport J.L., Delisi L.E., Krebs M.O.,
RA   Mouaffak F., Joober R., Mottron L., Drapeau P., Marineau C.,
RA   Lafreniere R.G., Lacaille J.C., Rouleau G.A., Michaud J.L.;
RT   "Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation.";
RL   N. Engl. J. Med. 360:599-605(2009).
RN   [6]
RP   INVOLVEMENT IN MRD5.
RX   PubMed=21076407; DOI=10.1038/ng.712;
RA   Vissers L.E., de Ligt J., Gilissen C., Janssen I., Steehouwer M.,
RA   de Vries P., van Lier B., Arts P., Wieskamp N., del Rosario M.,
RA   van Bon B.W., Hoischen A., de Vries B.B., Brunner H.G., Veltman J.A.;
RT   "A de novo paradigm for mental retardation.";
RL   Nat. Genet. 42:1109-1112(2010).
RN   [7]
RP   INVOLVEMENT IN MRD5, AND VARIANTS ARG-991 AND THR-1115.
RX   PubMed=21237447; DOI=10.1016/j.biopsych.2010.11.015;
RA   Hamdan F.F., Daoud H., Piton A., Gauthier J., Dobrzeniecka S., Krebs M.O.,
RA   Joober R., Lacaille J.C., Nadeau A., Milunsky J.M., Wang Z., Carmant L.,
RA   Mottron L., Beauchamp M.H., Rouleau G.A., Michaud J.L.;
RT   "De novo SYNGAP1 mutations in nonsyndromic intellectual disability and
RT   autism.";
RL   Biol. Psychiatry 69:898-901(2011).
RN   [8]
RP   VARIANTS MRD5 ARG-362 AND LEU-562, AND CHARACTERIZATION OF VARIANTS MRD5
RP   ARG-362 AND LEU-562.
RX   PubMed=23161826; DOI=10.1002/humu.22248;
RA   Berryer M.H., Hamdan F.F., Klitten L.L., Moller R.S., Carmant L.,
RA   Schwartzentruber J., Patry L., Dobrzeniecka S., Rochefort D.,
RA   Neugnot-Cerioli M., Lacaille J.C., Niu Z., Eng C.M., Yang Y., Palardy S.,
RA   Belhumeur C., Rouleau G.A., Tommerup N., Immken L., Beauchamp M.H.,
RA   Patel G.S., Majewski J., Tarnopolsky M.A., Scheffzek K., Hjalgrim H.,
RA   Michaud J.L., Di Cristo G.;
RT   "Mutations in SYNGAP1 cause intellectual disability, autism, and a specific
RT   form of epilepsy by inducing haploinsufficiency.";
RL   Hum. Mutat. 34:385-394(2013).
RN   [9]
RP   VARIANTS MRD5 143-ARG--HIS-1343 DEL; 267-TRP--HIS-1343 DEL AND
RP   701-PRO--HIS-1343 DEL.
RX   PubMed=23708187; DOI=10.1038/ng.2646;
RA   Carvill G.L., Heavin S.B., Yendle S.C., McMahon J.M., O'Roak B.J., Cook J.,
RA   Khan A., Dorschner M.O., Weaver M., Calvert S., Malone S., Wallace G.,
RA   Stanley T., Bye A.M., Bleasel A., Howell K.B., Kivity S., Mackay M.T.,
RA   Rodriguez-Casero V., Webster R., Korczyn A., Afawi Z., Zelnick N.,
RA   Lerman-Sagie T., Lev D., Moeller R.S., Gill D., Andrade D.M., Freeman J.L.,
RA   Sadleir L.G., Shendure J., Berkovic S.F., Scheffer I.E., Mefford H.C.;
RT   "Targeted resequencing in epileptic encephalopathies identifies de novo
RT   mutations in CHD2 and SYNGAP1.";
RL   Nat. Genet. 45:825-830(2013).
RN   [10]
RP   VARIANTS GLN-170 AND PRO-195.
RX   PubMed=27864847; DOI=10.1002/humu.23149;
RG   Clinical Study Group;
RA   Parrini E., Marini C., Mei D., Galuppi A., Cellini E., Pucatti D.,
RA   Chiti L., Rutigliano D., Bianchini C., Virdo S., De Vita D., Bigoni S.,
RA   Barba C., Mari F., Montomoli M., Pisano T., Rosati A., Guerrini R.;
RT   "Diagnostic targeted resequencing in 349 patients with drug-resistant
RT   pediatric epilepsies identifies causative mutations in 30 different
RT   genes.";
RL   Hum. Mutat. 38:216-225(2017).
CC   -!- FUNCTION: Major constituent of the PSD essential for postsynaptic
CC       signaling. Inhibitory regulator of the Ras-cAMP pathway. Member of the
CC       NMDAR signaling complex in excitatory synapses, it may play a role in
CC       NMDAR-dependent control of AMPAR potentiation, AMPAR membrane
CC       trafficking and synaptic plasticity. Regulates AMPAR-mediated miniature
CC       excitatory postsynaptic currents. Exhibits dual GTPase-activating
CC       specificity for Ras and Rap. May be involved in certain forms of brain
CC       injury, leading to long-term learning and memory deficits (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with KLHL17, CAMK2A and CAMK2B (By similarity).
CC       Interacts with MPDZ (PubMed:15312654). Interacts with FAM81A; the
CC       interaction facilitates condensate formation via liquid-liquid phase
CC       separation (By similarity). {ECO:0000250|UniProtKB:F6SEU4,
CC       ECO:0000250|UniProtKB:Q9QUH6, ECO:0000269|PubMed:15312654}.
CC   -!- INTERACTION:
CC       Q96PV0; O60716: CTNND1; NbExp=4; IntAct=EBI-2682386, EBI-701927;
CC       Q96PV0; Q5JVL4: EFHC1; NbExp=3; IntAct=EBI-2682386, EBI-743105;
CC       Q96PV0; Q14576: ELAVL3; NbExp=7; IntAct=EBI-2682386, EBI-749673;
CC       Q96PV0; O95208: EPN2; NbExp=2; IntAct=EBI-2682386, EBI-11081732;
CC       Q96PV0; Q06787: FMR1; NbExp=3; IntAct=EBI-2682386, EBI-366305;
CC       Q96PV0; P51114: FXR1; NbExp=4; IntAct=EBI-2682386, EBI-713291;
CC       Q96PV0; P09471: GNAO1; NbExp=4; IntAct=EBI-2682386, EBI-715087;
CC       Q96PV0; Q96NT3-2: GUCD1; NbExp=3; IntAct=EBI-2682386, EBI-11978177;
CC       Q96PV0; P10412: H1-4; NbExp=2; IntAct=EBI-2682386, EBI-358163;
CC       Q96PV0; O60741: HCN1; NbExp=3; IntAct=EBI-2682386, EBI-11173743;
CC       Q96PV0; P22626: HNRNPA2B1; NbExp=4; IntAct=EBI-2682386, EBI-299649;
CC       Q96PV0; O75031: HSF2BP; NbExp=3; IntAct=EBI-2682386, EBI-7116203;
CC       Q96PV0; P61371: ISL1; NbExp=8; IntAct=EBI-2682386, EBI-3906896;
CC       Q96PV0; Q86U70: LDB1; NbExp=9; IntAct=EBI-2682386, EBI-677177;
CC       Q96PV0; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-2682386, EBI-10172526;
CC       Q96PV0; Q13064: MKRN3; NbExp=3; IntAct=EBI-2682386, EBI-2340269;
CC       Q96PV0; O43639: NCK2; NbExp=3; IntAct=EBI-2682386, EBI-713635;
CC       Q96PV0; Q7Z3B1: NEGR1; NbExp=4; IntAct=EBI-2682386, EBI-4314838;
CC       Q96PV0; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-2682386, EBI-741158;
CC       Q96PV0; Q8TAQ2: SMARCC2; NbExp=3; IntAct=EBI-2682386, EBI-357418;
CC       Q96PV0; Q99932-2: SPAG8; NbExp=3; IntAct=EBI-2682386, EBI-11959123;
CC       Q96PV0; P51687: SUOX; NbExp=3; IntAct=EBI-2682386, EBI-3921347;
CC       Q96PV0; O43711: TLX3; NbExp=3; IntAct=EBI-2682386, EBI-3939165;
CC       Q96PV0; P14373: TRIM27; NbExp=3; IntAct=EBI-2682386, EBI-719493;
CC       Q96PV0; Q96PN8: TSSK3; NbExp=3; IntAct=EBI-2682386, EBI-3918381;
CC       Q96PV0; O95231: VENTX; NbExp=3; IntAct=EBI-2682386, EBI-10191303;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q96PV0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96PV0-2; Sequence=VSP_007973;
CC       Name=3;
CC         IsoId=Q96PV0-3; Sequence=VSP_026376;
CC       Name=4;
CC         IsoId=Q96PV0-4; Sequence=VSP_026377;
CC   -!- DOMAIN: The C2 domain is required for RapGAP activity. {ECO:0000250}.
CC   -!- PTM: Phosphorylated by CaM-kinase II. Dephosphorylated upon NMDA
CC       receptor activation or SYNGAP1/MPDZ complex disruption. Phosphorylation
CC       by PLK2 promotes its activity (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 5
CC       (MRD5) [MIM:612621]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period. MRD5
CC       patients show global developmental delay with delayed motor
CC       development, hypotonia, moderate-to-severe intellectual disability, and
CC       severe language impairment. Epilepsy and autism can be present in some
CC       patients. {ECO:0000269|PubMed:19196676, ECO:0000269|PubMed:21076407,
CC       ECO:0000269|PubMed:21237447, ECO:0000269|PubMed:23161826,
CC       ECO:0000269|PubMed:23708187}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-16 is the initiator
CC       methionine. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB67831.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Synaptic Ras GTPase activating protein 1 homolog
CC       (rat) (SYNGAP1); Note=Leiden Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/SYNGAP1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB067525; BAB67831.2; ALT_INIT; mRNA.
DR   EMBL; AL021366; CAA16161.1; -; Genomic_DNA.
DR   EMBL; AL662799; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX088650; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL713634; CAD28452.1; -; mRNA.
DR   CCDS; CCDS34434.2; -. [Q96PV0-1]
DR   RefSeq; NP_001123538.1; NM_001130066.1.
DR   RefSeq; NP_006763.2; NM_006772.3. [Q96PV0-1]
DR   RefSeq; XP_047275414.1; XM_047419458.1. [Q96PV0-4]
DR   RefSeq; XP_047275417.1; XM_047419461.1. [Q96PV0-2]
DR   RefSeq; XP_047275419.1; XM_047419463.1. [Q96PV0-2]
DR   RefSeq; XP_047275420.1; XM_047419464.1. [Q96PV0-2]
DR   RefSeq; XP_054212635.1; XM_054356660.1. [Q96PV0-4]
DR   RefSeq; XP_054212637.1; XM_054356662.1. [Q96PV0-2]
DR   RefSeq; XP_054212639.1; XM_054356664.1. [Q96PV0-2]
DR   RefSeq; XP_054212640.1; XM_054356665.1. [Q96PV0-2]
DR   AlphaFoldDB; Q96PV0; -.
DR   SMR; Q96PV0; -.
DR   BioGRID; 114358; 54.
DR   FunCoup; Q96PV0; 1087.
DR   IntAct; Q96PV0; 463.
DR   MINT; Q96PV0; -.
DR   STRING; 9606.ENSP00000496007; -.
DR   GlyCosmos; Q96PV0; 5 sites, 1 glycan.
DR   GlyGen; Q96PV0; 21 sites, 1 O-linked glycan (20 sites).
DR   iPTMnet; Q96PV0; -.
DR   PhosphoSitePlus; Q96PV0; -.
DR   SwissPalm; Q96PV0; -.
DR   BioMuta; SYNGAP1; -.
DR   DMDM; 150421676; -.
DR   jPOST; Q96PV0; -.
DR   MassIVE; Q96PV0; -.
DR   PaxDb; 9606-ENSP00000403636; -.
DR   PeptideAtlas; Q96PV0; -.
DR   ProteomicsDB; 77769; -. [Q96PV0-1]
DR   ProteomicsDB; 77770; -. [Q96PV0-2]
DR   ProteomicsDB; 77771; -. [Q96PV0-3]
DR   ProteomicsDB; 77772; -. [Q96PV0-4]
DR   Antibodypedia; 29204; 247 antibodies from 34 providers.
DR   DNASU; 8831; -.
DR   Ensembl; ENST00000395071.6; ENSP00000378509.2; ENSG00000227460.8. [Q96PV0-4]
DR   Ensembl; ENST00000414753.6; ENSP00000407995.2; ENSG00000227460.8. [Q96PV0-3]
DR   Ensembl; ENST00000418600.7; ENSP00000403636.3; ENSG00000197283.18. [Q96PV0-2]
DR   Ensembl; ENST00000428982.4; ENSP00000412475.2; ENSG00000197283.18. [Q96PV0-3]
DR   Ensembl; ENST00000455687.6; ENSP00000414259.2; ENSG00000227460.8. [Q96PV0-1]
DR   Ensembl; ENST00000628646.2; ENSP00000486431.1; ENSG00000197283.18. [Q96PV0-4]
DR   Ensembl; ENST00000629380.3; ENSP00000486463.1; ENSG00000197283.18. [Q96PV0-1]
DR   Ensembl; ENST00000646630.1; ENSP00000496007.1; ENSG00000197283.18. [Q96PV0-1]
DR   GeneID; 8831; -.
DR   KEGG; hsa:8831; -.
DR   MANE-Select; ENST00000646630.1; ENSP00000496007.1; NM_006772.3; NP_006763.2.
DR   UCSC; uc010juz.4; human. [Q96PV0-1]
DR   AGR; HGNC:11497; -.
DR   CTD; 8831; -.
DR   DisGeNET; 8831; -.
DR   GeneCards; SYNGAP1; -.
DR   GeneReviews; SYNGAP1; -.
DR   HGNC; HGNC:11497; SYNGAP1.
DR   HPA; ENSG00000197283; Low tissue specificity.
DR   MalaCards; SYNGAP1; -.
DR   MIM; 603384; gene.
DR   MIM; 612621; phenotype.
DR   neXtProt; NX_Q96PV0; -.
DR   OpenTargets; ENSG00000197283; -.
DR   Orphanet; 1942; Epilepsy with myoclonic-atonic seizures.
DR   Orphanet; 442835; Non-specific early-onset epileptic encephalopathy.
DR   Orphanet; 544254; SYNGAP1-related developmental and epileptic encephalopathy.
DR   PharmGKB; PA36279; -.
DR   VEuPathDB; HostDB:ENSG00000197283; -.
DR   eggNOG; KOG3508; Eukaryota.
DR   GeneTree; ENSGT00940000158438; -.
DR   HOGENOM; CLU_001727_1_1_1; -.
DR   InParanoid; Q96PV0; -.
DR   OMA; DPCVNTE; -.
DR   OrthoDB; 5572587at2759; -.
DR   PAN-GO; Q96PV0; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; Q96PV0; -.
DR   TreeFam; TF105303; -.
DR   PathwayCommons; Q96PV0; -.
DR   Reactome; R-HSA-5658442; Regulation of RAS by GAPs.
DR   SignaLink; Q96PV0; -.
DR   SIGNOR; Q96PV0; -.
DR   BioGRID-ORCS; 8831; 17 hits in 1149 CRISPR screens.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   GeneWiki; SYNGAP1; -.
DR   GenomeRNAi; 8831; -.
DR   Pharos; Q96PV0; Tbio.
DR   PRO; PR:Q96PV0; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q96PV0; protein.
DR   Bgee; ENSG00000197283; Expressed in pituitary gland and 99 other cell types or tissues.
DR   ExpressionAtlas; Q96PV0; baseline and differential.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IEA:GOC.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0005096; F:GTPase activator activity; IEA:UniProtKB-KW.
DR   GO; GO:0017124; F:SH3 domain binding; IEA:UniProtKB-KW.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0016358; P:dendrite development; IEA:Ensembl.
DR   GO; GO:0098880; P:maintenance of postsynaptic specialization structure; IEA:Ensembl.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0046580; P:negative regulation of Ras protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0007389; P:pattern specification process; IEA:Ensembl.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEA:Ensembl.
DR   GO; GO:0043113; P:receptor clustering; IEA:Ensembl.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IEA:Ensembl.
DR   GO; GO:0050803; P:regulation of synapse structure or activity; IEA:Ensembl.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; ISS:UniProtKB.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   CDD; cd04013; C2_SynGAP_like; 1.
DR   CDD; cd13375; PH_SynGAP; 1.
DR   CDD; cd05136; RasGAP_DAB2IP; 1.
DR   CDD; cd22265; UDM1_RNF168; 1.
DR   FunFam; 1.10.506.10:FF:000001; Ras GTPase-activating protein nGAP isoform 2; 1.
DR   FunFam; 2.60.40.150:FF:000010; Ras GTPase-activating protein nGAP isoform 2; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 1.10.506.10; GTPase Activation - p120gap, domain 1; 2.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR021887; DAB2P_C.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR039360; Ras_GTPase.
DR   InterPro; IPR023152; RasGAP_CS.
DR   InterPro; IPR001936; RasGAP_dom.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR037779; SynGAP_PH.
DR   PANTHER; PTHR10194; RAS GTPASE-ACTIVATING PROTEINS; 1.
DR   PANTHER; PTHR10194:SF25; RAS_RAP GTPASE-ACTIVATING PROTEIN SYNGAP; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF12004; DAB2P_C; 1.
DR   Pfam; PF25321; PH_RASGAP; 1.
DR   Pfam; PF00616; RasGAP; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00323; RasGAP; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF48350; GTPase activation domain, GAP; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00509; RAS_GTPASE_ACTIV_1; 1.
DR   PROSITE; PS50018; RAS_GTPASE_ACTIV_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Autism; Autism spectrum disorder; Disease variant;
KW   GTPase activation; Intellectual disability; Phosphoprotein;
KW   Proteomics identification; Reference proteome; SH3-binding.
FT   CHAIN           1..1343
FT                   /note="Ras/Rap GTPase-activating protein SynGAP"
FT                   /id="PRO_0000056654"
FT   DOMAIN          150..251
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          242..363
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          459..667
FT                   /note="Ras-GAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00167"
FT   REGION          92..129
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          373..394
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          725..753
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          781..805
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          933..1017
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1033..1154
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1274..1343
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           785..815
FT                   /note="SH3-binding"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        92..102
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        943..952
FT                   /note="Gly residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        956..967
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1048..1063
FT                   /note="Gly residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1072..1096
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1114..1129
FT                   /note="Gly residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1133..1148
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1274..1296
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            485
FT                   /note="Arginine finger; crucial for GTP hydrolysis by
FT                   stabilizing the transition state"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00167"
FT   MOD_RES         34
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         39
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         117
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         371
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         379
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         385
FT                   /note="Phosphoserine; by PLK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         449
FT                   /note="Phosphoserine; by PLK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         466
FT                   /note="Phosphoserine; by PLK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         752
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         766
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         780
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         823
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         825
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         828
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         836
FT                   /note="Phosphoserine; by PLK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         840
FT                   /note="Phosphoserine; by PLK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         842
FT                   /note="Phosphoserine; by PLK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         876
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         892
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         895
FT                   /note="Phosphoserine; by PLK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         898
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         985
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         1114
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         1118
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         1121
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QUH6"
FT   MOD_RES         1165
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   MOD_RES         1204
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:F6SEU4"
FT   VAR_SEQ         1..98
FT                   /note="MSRSRASIHRGSIPAMSYAPFRDVRGPSMHRTQYVHSPYDRPGWNPRFCIIS
FT                   GNQLLMLDEDEIHPLLIRDRRSESSRNKLLRRTVSVPVEGRPHGEH -> MGLRPPTPS
FT                   PSGGSCSGSLPPPSRCQPLRRRCSSCCFPG (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_026376"
FT   VAR_SEQ         1265..1343
FT                   /note="RLMLVEEELRRDHPAMAEPLPEPKKRLLDAQERQLPPLGPTNPRVTLAPPWN
FT                   GLAPPAPPPPPRLQITENGEFRNTADH -> SPSLQADAGGGGAAPGPPRHG (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_007973"
FT   VAR_SEQ         1296..1343
FT                   /note="ERQLPPLGPTNPRVTLAPPWNGLAPPAPPPPPRLQITENGEFRNTADH ->
FT                   LLIR (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_026377"
FT   VARIANT         143..1343
FT                   /note="Missing (in MRD5; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078616"
FT   VARIANT         170
FT                   /note="R -> Q (found in a patient with drug-resistant
FT                   generalized epilepsy, cognitive impairment and autism
FT                   spectrum disorder; likely pathogenic; dbSNP:rs1057519546)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078233"
FT   VARIANT         195
FT                   /note="A -> P (found in a patient with West syndrome;
FT                   likely pathogenic; dbSNP:rs1057519545)"
FT                   /evidence="ECO:0000269|PubMed:27864847"
FT                   /id="VAR_078234"
FT   VARIANT         201
FT                   /note="D -> E (in dbSNP:rs768682743)"
FT                   /evidence="ECO:0000269|PubMed:19196676"
FT                   /id="VAR_065078"
FT   VARIANT         267..1343
FT                   /note="Missing (in MRD5)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078617"
FT   VARIANT         362
FT                   /note="W -> R (in MRD5; the mutant protein is less
FT                   efficient in inhibiting ERK phosphorylation induced by
FT                   neuronal activity)"
FT                   /evidence="ECO:0000269|PubMed:23161826"
FT                   /id="VAR_069232"
FT   VARIANT         562
FT                   /note="P -> L (in MRD5; the mutant protein is less
FT                   efficient in inhibiting ERK phosphorylation induced by
FT                   neuronal activity; dbSNP:rs397514670)"
FT                   /evidence="ECO:0000269|PubMed:23161826"
FT                   /id="VAR_069233"
FT   VARIANT         701..1343
FT                   /note="Missing (in MRD5)"
FT                   /evidence="ECO:0000269|PubMed:23708187"
FT                   /id="VAR_078618"
FT   VARIANT         749
FT                   /note="R -> Q"
FT                   /evidence="ECO:0000269|PubMed:19196676"
FT                   /id="VAR_065079"
FT   VARIANT         790
FT                   /note="T -> N (in dbSNP:rs552867155)"
FT                   /evidence="ECO:0000269|PubMed:19196676"
FT                   /id="VAR_065080"
FT   VARIANT         991
FT                   /note="G -> R (in dbSNP:rs145472959)"
FT                   /evidence="ECO:0000269|PubMed:21237447"
FT                   /id="VAR_065081"
FT   VARIANT         1115
FT                   /note="I -> T (in dbSNP:rs191549504)"
FT                   /evidence="ECO:0000269|PubMed:19196676,
FT                   ECO:0000269|PubMed:21237447"
FT                   /id="VAR_065082"
FT   VARIANT         1283
FT                   /note="P -> L (in dbSNP:rs1396355432)"
FT                   /evidence="ECO:0000269|PubMed:19196676"
FT                   /id="VAR_065083"
FT   VARIANT         1310
FT                   /note="T -> M (in dbSNP:rs796430835)"
FT                   /evidence="ECO:0000269|PubMed:19196676"
FT                   /id="VAR_065084"
SQ   SEQUENCE   1343 AA;  148284 MW;  D9ABE21054677AA0 CRC64;
     MSRSRASIHR GSIPAMSYAP FRDVRGPSMH RTQYVHSPYD RPGWNPRFCI ISGNQLLMLD
     EDEIHPLLIR DRRSESSRNK LLRRTVSVPV EGRPHGEHEY HLGRSRRKSV PGGKQYSMEG
     APAAPFRPSQ GFLSRRLKSS IKRTKSQPKL DRTSSFRQIL PRFRSADHDR ARLMQSFKES
     HSHESLLSPS SAAEALELNL DEDSIIKPVH SSILGQEFCF EVTTSSGTKC FACRSAAERD
     KWIENLQRAV KPNKDNSRRV DNVLKLWIIE ARELPPKKRY YCELCLDDML YARTTSKPRS
     ASGDTVFWGE HFEFNNLPAV RALRLHLYRD SDKKRKKDKA GYVGLVTVPV ATLAGRHFTE
     QWYPVTLPTG SGGSGGMGSG GGGGSGGGSG GKGKGGCPAV RLKARYQTMS ILPMELYKEF
     AEYVTNHYRM LCAVLEPALN VKGKEEVASA LVHILQSTGK AKDFLSDMAM SEVDRFMERE
     HLIFRENTLA TKAIEEYMRL IGQKYLKDAI GEFIRALYES EENCEVDPIK CTASSLAEHQ
     ANLRMCCELA LCKVVNSHCV FPRELKEVFA SWRLRCAERG REDIADRLIS ASLFLRFLCP
     AIMSPSLFGL MQEYPDEQTS RTLTLIAKVI QNLANFSKFT SKEDFLGFMN EFLELEWGSM
     QQFLYEISNL DTLTNSSSFE GYIDLGRELS TLHALLWEVL PQLSKEALLK LGPLPRLLND
     ISTALRNPNI QRQPSRQSER PRPQPVVLRG PSAEMQGYMM RDLNSSIDLQ SFMARGLNSS
     MDMARLPSPT KEKPPPPPPG GGKDLFYVSR PPLARSSPAY CTSSSDITEP EQKMLSVNKS
     VSMLDLQGDG PGGRLNSSSV SNLAAVGDLL HSSQASLTAA LGLRPAPAGR LSQGSGSSIT
     AAGMRLSQMG VTTDGVPAQQ LRIPLSFQNP LFHMAADGPG PPGGHGGGGG HGPPSSHHHH
     HHHHHHRGGE PPGDTFAPFH GYSKSEDLSS GVPKPPAASI LHSHSYSDEF GPSGTDFTRR
     QLSLQDNLQH MLSPPQITIG PQRPAPSGPG GGSGGGSGGG GGGQPPPLQR GKSQQLTVSA
     AQKPRPSSGN LLQSPEPSYG PARPRQQSLS KEGSIGGSGG SGGGGGGGLK PSITKQHSQT
     PSTLNPTMPA SERTVAWVSN MPHLSADIES AHIEREEYKL KEYSKSMDES RLDRVKEYEE
     EIHSLKERLH MSNRKLEEYE RRLLSQEEQT SKILMQYQAR LEQSEKRLRQ QQAEKDSQIK
     SIIGRLMLVE EELRRDHPAM AEPLPEPKKR LLDAQERQLP PLGPTNPRVT LAPPWNGLAP
     PAPPPPPRLQ ITENGEFRNT ADH
//
